The healthcare industry is experiencing a fundamental transformation — a shift from the traditional fee-for-service model to ...
Mechelen, Belgium; November 3, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the ...
Money Talks News on MSN
30 high-paying remote jobs with salaries of $100,000 (or higher)
High-paying remote finance director jobs often involve managing accounting and financial control functions, establishing ...
PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview ...
Companies this past month announced many new products and services that use artificial intelligence to automate complex processes, secure data and improve care coordination and interoperability ...
Discover Revvity, Inc.’s latest earnings, cloud growth, and $1B buyback. Click for my updated look at RVTY stock and why I ...
19 小时on MSN
Schrödinger updates 2025 software growth guidance to 8%-13% amid pharma scale-up delays ...
Q3 2025 Management View CEO Ramy Farid reported "very solid progress during the third quarter," highlighting total revenue of $54 million, a 54% increase from the third quarter of 2024. Software ...
With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...
Professionals have the satisfaction of knowing their efforts lead to tangible improvements in lives and communities.
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- ...
Whether you're recruiting new talent or looking to make payroll more efficient, these companies can help reach your goals.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果